Company intelligence / Profile preview

Axon Neuroscience

Bratislava, Slovakiaaxon-neuroscience.eu ↗

Ownership: Private
Development stage: Other

Overview

Axon Neuroscience’s lead asset, AADvac1, is an active immunotherapy targeting pathological tau proteins. In the completed Phase II ADAMANT trial in Alzheimer’s disease, AADvac1 demonstrated a favorable safety profile and robust immune response with statistically significant slowing of neurodegeneration as measured by neurofilament light chain. Clinical benefit was most pronounced in biomarker-defined subgroups. The company has also been selected to participate in a major NIH-funded platform trial for progressive supranuclear palsy starting late 2025.

Therapeutic areas: Neurology
Modalities: VaccineMonoclonal antibodyImmunotherapy
Industry: Biotech

Drug pipeline

6 assets

AADvac1

5 more assets in the full pipeline.

Partnerships

National Institute on Aging / NIH-funded PSP Platform Trial

Beyond the preview

Go deeper on Axon Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axon Neuroscience.